Precigen's PAPZIMEOS, the first FDA-approved treatment for adults with recurrent respiratory papillomatosis (RRP), generated $21.6 million in net product revenue in Q1 2026, reflecting strong uptake across the US including community settings. With approximately 400 patients enrolled in its patient hub and broad payer coverage, PAPZIMEOS is becoming the standard first-line treatment for RRP. The company expects its current cash and PAPZIMEOS revenue to fund operations to cash flow break-even by the end of 2026. Precigen also continues advancing its AdenoVerse platform, including PRGN-2009 for HPV-associated cancers, with updates expected later this year.
A regional nonprofit health plan reduced its Transparency in Coverage machine-readable file (MRF) production time from 45 days to less than 24 hours by integrating TALON's platform directly with its claims administration system. This eliminated a com...
ASUS has introduced two new Chromebooks in the US market: the budget-friendly CM15 laptop and the versatile CM32 Detachable 2-in-1 device. Both run on the MediaTek Kompanio 540 processor, offer up to 12 hours of battery life, and feature military-gra...
Slate Medicines, a biotech firm focused on migraine treatments, has appointed Mark W. Hahn to its Board of Directors. Hahn brings over 25 years of experience in life sciences, including leading companies through financial milestones and FDA approvals...
The global clinical trials market is projected to grow from $135.51 billion in 2026 to $176.32 billion by 2030, at a CAGR of 6.8%. Growth is fueled by advances in AI-enabled trial design, decentralized and hybrid trial platforms, and increasing deman...
The global hybrid robots market is projected to grow from $5.68 billion in 2026 to $10.03 billion by 2030, with a CAGR of 15.3%. Growth is fueled by advances in AI, autonomous operations, and smart manufacturing, alongside rising demand for robots in...
